This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Guardian Pharmacy Services Ends Controlled Company Status on NYSE

Tipranks - Tue Mar 24, 4:06PM CDT

Claim 30% Off TipRanks Premium

Guardian Pharmacy Services, Inc. Class A ( (GRDN) ) has provided an announcement.

On March 18, 2026, Guardian Pharmacy Services entered into stock purchase agreements with certain Class A shareholders, enabling the company to repurchase up to 1,833,344 shares in private transactions at prices tied to future underwritten offerings, while those holders agreed to a lock-up extending at least until June 30, 2026. On March 20, 2026, the company completed an underwritten offering of 6.9 million Class A shares, used its proceeds from 1.02 million newly issued shares to buy and cancel an equal number of outstanding shares with no net change in shares outstanding, and, as selling stockholders lost majority voting control, Guardian ceased to qualify as a NYSE “controlled company” and promptly formed an independent Nominating and Governance Committee to comply with full exchange governance requirements.

The most recent analyst rating on (GRDN) stock is a Hold with a $37.00 price target. To see the full list of analyst forecasts on Guardian Pharmacy Services, Inc. Class A stock, see the GRDN Stock Forecast page.

Spark’s Take on GRDN Stock

According to Spark, TipRanks’ AI Analyst, GRDN is a Neutral.

The score is driven primarily by improving fundamentals (strong cash generation and a significantly strengthened balance sheet) and supportive technical momentum. This is tempered by a high P/E valuation and policy/operational headwinds highlighted on the earnings call (IRA impacts and some nonrecurring recent benefits).

To see Spark’s full report on GRDN stock, click here.

More about Guardian Pharmacy Services, Inc. Class A

Guardian Pharmacy Services, Inc. operates in the pharmacy services industry, providing medication management and related pharmacy solutions, with its equity traded on the New York Stock Exchange. The company’s capital structure includes Class A common stock held by public investors and former Class B shares converted in connection with a 2024 corporate reorganization, and it is now subject to standard NYSE corporate governance rules following the loss of controlled company status.

Average Trading Volume: 308,605

Technical Sentiment Signal: Buy

Current Market Cap: $2.26B

For an in-depth examination of GRDN stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.